The runner's high probably isn't an endorphin rush, studies suggest

The pleasant, floaty calm some people feel after a long run — the "runner's high" — probably is not caused by endorphins, despite that being the textbook explanation for decades. Two independent lines of evidence now point instead to endocannabinoids, the body's own cannabis-like signalling molecules [s1] [s2].

The endorphin story took hold because exercise raises blood levels of β-endorphin, an opioid, and the timing seemed to fit the mood lift [s2]. But there was always a physiological problem with it. β-endorphin is a large molecule that does not readily cross the blood–brain barrier, so its concentration in the bloodstream may say little about what is happening in the brain, where a mood is actually generated [s2] [s3]. A rise you can measure in a blood sample is not the same as a drug reaching the neurons that would produce euphoria.

The mouse experiment

The cleaner test came in mice, because researchers can block specific receptors and knock out specific genes. Running raised blood levels of both β-endorphin and anandamide, an endocannabinoid, in the animals [s2]. Using a combination of drugs and genetic engineering, the team showed that two core features of the runner's high — reduced anxiety and reduced pain sensitivity — depended on cannabinoid receptors, not opioid receptors [s2]. The anxiety-lowering effect required intact cannabinoid receptor 1 (CB1) receptors on a class of forebrain neurons; the pain relief required peripheral CB1 and CB2 receptors [s2]. Sedation, by contrast, was not affected by blocking either system, and euphoria simply cannot be studied in a mouse [s2]. The endocannabinoid system, in other words, was doing the work the endorphins had been credited with.

The human experiment

Mice cannot report feeling good, so the decisive human question was whether blocking opioids would abolish the high in people. Researchers ran a double-blind, randomised, placebo- controlled trial in 63 participants, giving them either the opioid-blocking drug naltrexone or a placebo before exercise [s1]. After 45 minutes of moderate-intensity treadmill running, participants reported more euphoria and less anxiety than after walking, and their blood showed higher levels of the endocannabinoids anandamide and 2-arachidonoylglycerol [s1].

The key result: blocking opioid signalling did not prevent any of it [s1]. Euphoria still rose, anxiety still fell, and endocannabinoid levels still climbed under naltrexone, and the share of participants reporting a subjective runner's high was comparable in the naltrexone and placebo groups [s1]. If endorphins were the cause, shutting down the opioid system should have blunted the effect; it did not.

What this does and does not establish

The honest reading is that opioids are not necessary for the runner's high in humans, and that endocannabinoids track it closely — making them strong candidates, as the mouse work already showed [s1]. It is not yet full proof of cause. The human study demonstrated that the high survives opioid blockade, but it did not directly block the endocannabinoid system in people to confirm the high disappears when they are removed [s1]. The effect also depends on dose and person: a moderate-intensity effort produced it here, not everyone experiences the same lift, and the mechanism behind sedation and other components may differ again [s1] [s2].

Why does the plumbing matter, if the good feeling is real either way? Because the mechanism gets attached to claims — the popular shorthand that exercise "releases endorphins" underpins a lot of wellness marketing, and it appears to be wrong. The genuinely well-supported case for exercise and mood does not rest on it: randomised evidence that exercise eases depression stands on clinical outcomes, not on a molecule, a point reinforced by two 2026 trials testing exercise against depression. The runner's high is a smaller, more specific phenomenon — and the endocannabinoids, not the endorphins, look like the better explanation for it.